These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 8136487)
41. Exporting DBCP and other banned pesticides: consideration of ethical issues. Lowry LK; Frank AL Int J Occup Environ Health; 1999; 5(2):135-41. PubMed ID: 10330515 [TBL] [Abstract][Full Text] [Related]
42. Mediating patienthood-from an ethics of to an ethics with technology. Kiran AH Nurs Philos; 2017 Jan; 18(1):. PubMed ID: 27682857 [TBL] [Abstract][Full Text] [Related]
43. The choice of prosthetic and orthotic technique for less developed countries: analysis and perspectives in Colombia. Vossberg A Prosthet Orthot Int; 1988 Aug; 12(2):96-100. PubMed ID: 3174412 [TBL] [Abstract][Full Text] [Related]
44. Cost effectiveness of phacoemulsification in developing countries. Tan CS Eye (Lond); 2010 Dec; 24(12):1827-8; author reply 1828. PubMed ID: 21057520 [No Abstract] [Full Text] [Related]
45. Assessing medical technology in less-developed countries. Sideman S; BenDak JD Int J Technol Assess Health Care; 1997; 13(3):463-70. PubMed ID: 9308274 [TBL] [Abstract][Full Text] [Related]
46. Drug supplies, management and manufacturing for local needs. The provision of pharmaceuticals by appropriate technology. Dunnill P Proc R Soc Lond B Biol Sci; 1980 Jul; 209(1174):153-7. PubMed ID: 6106936 [TBL] [Abstract][Full Text] [Related]
47. MANAGEMENT OF MEDICAL TECHNOLOGY: AN ENIGMA. Matwankar S Med J Armed Forces India; 1996 Jul; 52(3):184-187. PubMed ID: 28769383 [TBL] [Abstract][Full Text] [Related]
48. The relativist stance. Rössler OE; Matsuno K Biosystems; 1998 Apr; 46(1-2):213-6. PubMed ID: 9648695 [TBL] [Abstract][Full Text] [Related]
49. Risk assessment and cost/benefit analysis for new regulations: Landrigan PJ New Solut; 1995 Jul; 5(4):85-91. PubMed ID: 22909460 [No Abstract] [Full Text] [Related]
50. Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries. Tachkov K; Zemplenyi A; Kamusheva M; Dimitrova M; Siirtola P; Pontén J; Nemeth B; Kalo Z; Petrova G Front Public Health; 2022; 10():921226. PubMed ID: 35910914 [TBL] [Abstract][Full Text] [Related]
51. "We noticed that suddenly the country has become full of MRI". Policy makers' views on diffusion and use of health technologies in Iran. Palesh M; Tishelman C; Fredrikson S; Jamshidi H; Tomson G; Emami A Health Res Policy Syst; 2010 Apr; 8():9. PubMed ID: 20370906 [TBL] [Abstract][Full Text] [Related]
52. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
53. Technology transfer to the developing world: does new technology have any relevance for developing countries? Basch PF Tuber Lung Dis; 1993 Dec; 74(6):353-8. PubMed ID: 8136487 [TBL] [Abstract][Full Text] [Related]
54. Ethical complexities of conducting research in developing countries. Varmus H; Satcher D N Engl J Med; 1997 Oct; 337(14):1003-5. PubMed ID: 9309109 [TBL] [Abstract][Full Text] [Related]
55. Technical fixes and other problems in saving lives in the world's poorest countries. Reich MR J Public Health Policy; 1988; 9(1):92-103. PubMed ID: 3360918 [TBL] [Abstract][Full Text] [Related]
56. What technologies for health care in developing countries? Perry S; Marx ES World Health Forum; 1992; 13(4):356-62. PubMed ID: 1466744 [TBL] [Abstract][Full Text] [Related]